Hiddo L. Heerspink PhDProfessor of Medicine, University of Groningen, University Medical Center Groningen, Groningen Netherlands
Hiddo Lambers Heerspink is Professor of Clinical Trials and Personalized Medicine and a clinical trialist at the Department of Clinical Pharmacy and Pharmacology at the University Medical Center Groningen. He is also visiting professor at the University of New South Wales in Sydney. He studied pharmacy at the University of Groningen and received his PhD from the University Medical Center Groningen.
Professor Lambers Heerspink’s research interests focus on optimizing current treatment strategies and finding new therapeutic approaches to halt the progression of kidney and cardiovascular diseases in patients with diabetes with a specific focus on personalized medicine. He leads numerous clinical trials with new interventions to reduce diabetes related kidney and cardiovascular complications. His main expertise includes clinical trial design, personalized medicine and methodological aspects and statistical analyses of clinical trials.
Professor L. Heerspink has authored and co-authored over 350 peer-reviewed publications and is editorial board member of Diabetes Obesity and Metabolism and the Clinical Journal of the American Society of Nephrology. Prof L. Heerspink is a consultant and has received honoraria from AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, CSL Pharma, Chinook, Dimerix, Janssen, Fresenius, Gilead, Merck, Mitsubishi Tanabe, Mundi Pharma, NovoNordisk and Travere Pharmaceuticals.
DisclosuresProf. Heerspink reports the following:
- Grants/contracts (payments to institution): AstraZeneca, Boehringer Ingelheim, Janssen, Novo Nordisk
- Consulting fees (payments to institution): AstraZeneca, Abbvie, Boehringer Ingelheim, CSL Behring, Bayer, Chinook, Dimerix, Gilead, Goldfinch, Merck, Novartis, NovoNordisk, Janssen, Traveere Pharmaceuticals
- Payment/honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (payments to institution/self): AstraZeneca